Calidi Biotherapeutics
CLDI
27 hedge funds and large institutions have $479K invested in Calidi Biotherapeutics in 2026 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 5 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 3
60% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 5
8% more funds holding
Funds holding: 25 → 27 (+2)
1.31% more ownership
Funds ownership: 0.39% → 1.7% (+1.3%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
9% less capital invested
Capital invested by funds: $525K → $479K (-$45.9K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$660K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$327K |
| 3 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
+$188K |
| 4 |
VF
Virtu Financial
New York
|
+$41K |
| 5 |
AAP
Arax Advisory Partners
Denver,
Colorado
|
+$28.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DS
DRW Securities
Chicago,
Illinois
|
-$173K |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$16.3K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$8.79K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1.03K |
| 5 |
BC
Barrett & Company
Providence,
Rhode Island
|
-$342 |
CLDI Hedge Fund Activity: Q1 2026 in Review
27 of the 8,191 institutional investors tracked by Wall St. Rank reported a position in Calidi Biotherapeutics (CLDI) for Q1 2026, worth a combined $479K — down 8.7% from $525K a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new CLDI positions and 5 closed out — a net gain of 3 holders — while 6 added to existing stakes and 3 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $660K. The largest seller was DRW Securities, exiting entirely with an estimated $173K sold.
- 27 institutional investors held Calidi Biotherapeutics (CLDI) as of Q1 2026, up from 25 in Q4 2025.
- Funds reported $479K of Calidi Biotherapeutics stock for Q1 2026, down 8.7% quarter-over-quarter.
- 8 funds opened new Calidi Biotherapeutics positions in Q1 2026 and 5 closed out, a net change of +3 holders.
- The largest Calidi Biotherapeutics buyer in Q1 2026 was Armistice Capital, an estimated $660K added.
- The largest Calidi Biotherapeutics seller in Q1 2026 was DRW Securities, an estimated $173K sold.
Based on aggregated 13F filings for Q1 2026.